Lundbeck could introduce gene chip-technology for depressive patients within ten years

Within the next ten years Danish company Lundbeck expects to be able to indicate to depressive patients exactly which type of medicine will work for them, simply by having them take a blood test. However, the pharmaceutical company has already lost the first round of the gene chip-race.

Foto: Helle Arensbak / Jyllands-Posten

There is a wide array of anti-depressants out there, but most of the time the drugs only work on a small segment of the depressive patients. Lundbeck is well on the way to discover a method to determine whether or not a patient suffers from depression, and if so, exactly which kind of depression.

“The work we are doing, internally, shows that depression is not just one condition. It is a number of different conditions. Bearing that in mind, I expect that what we’ll see in the future are drugs aimed at different patient groups,” Head of Research for Lundbeck, Peter Høngaard Andersen, tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier